ScreenPoint raises $16M for breast AI expansion

ScreenPoint Medical has raised $16M to support product development and international expansion of its Transpara breast AI solutions.

The funding includes $14M from existing investors Insight Partners and Siemens Healthineers. The company also reported $2M in non-dilutive research grants.

ScreenPoint said Transpara Breast AI is deployed in more than 30 countries and has processed more than 12M mammograms to date. The software is CE-marked and FDA-cleared for 2D and 3D mammography, according to the company.

The announcement follows recent research milestones for the platform. Final results from the MASAI randomized controlled trial were published in The Lancet in January. ScreenPoint said the trial found consistently favorable outcomes compared with standard double reading, including effects on cancer detection and workload reduction.

A separate prospective study published in Nature Medicine evaluated AI-based triage and decision support in mammography and digital breast tomosynthesis. The study reported a 63.6% lower radiologist workload and a 15.2% higher cancer detection rate under the AI strategy.

In npj Digital Medicine, researchers compared 4 breast cancer risk prediction algorithms using 112,621 negative mammograms from 2 UK NHS Breast Screening Programme sites. Within the highest 14% of risk scores, the top algorithm identified 41.8% of future cancers and 50.3% of interval cancers.

ScreenPoint said its image-based risk algorithm outperformed Mirai, iCAD, and Google at 5-year risk prediction. The company noted that the risk algorithm is for investigational use only.

The company said the new capital will support product innovation, international expansion, and strategic initiatives for breast cancer detection and risk assessment.